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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
that causes coronavirus disease 2019 (COVID-19) has infected more 
than 23 million people globally resulting in the death of over 800,000 
subjects. It has inflicted severe public health and economic hardships 
across the world. In addition to acute respiratory distress syndrome, 
respiratory failure, sepsis, and acute kidney injury, COVID-19 also 
causes heart failure (HF). COVID-19-induced HF is manifested via 
different mechanisms, including, but not limited to, (1) virus-induced 
infiltration of inflammatory cells, which could impair the function of the 
heart; (2) pro-inflammatory cytokines (monocyte chemoattractant 
protein-1, interleukin-1β; interleukin-6; tumor necrosis factor-α) that 
could cause necrosis and death of the myocardium; (3) endothelial injury 
coupled with micro-thrombosis which could damage the endocardium; 
and (4) acute respiratory distress syndrome and respiratory failure that 
could lead to heart failure due to severe hypoxia. It is concluded that the 
etiology of COVID-19-induced HF is multifactorial and mitigation of 
the development of HF in patients with COVID-19 will require different 
approaches such as social distancing, drug therapy, and the urgent 










Coronavirus Disease 2019 (COVID-19) caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in 
Wuhan, China, in December 2019 [1]. Since then COVID-19 has spread 
across the globe and has caused a serious pandemic that has adversely 
affected the livelihood of millions of people and the economy of many 
nations. As of August 24, 2020, SARS-CoV-2 has infected 23,736,062 
million people with 814,751 deaths worldwide [2]. According to the US 
Center for Disease Control, more than 5,682,491 million American 
residents carry the disease, which has resulted in 176,223 deaths at the 
time of revising this review (August 24, 2020) [3].
The virus that causes COVID-19 is transmitted through respiratory 
aerosols or physical contact with contaminated droplets [4]. SARS-CoV-2 
virus then finds its way into the respiratory system, where they induce a 
cascade of inflammatory reactions [4]. SARS-CoV-2-induced COVID-19 
has caused a large variety of complications resulting in high morbidity and 
mortality. COVID-19-induced pathologies are not limited to the respiratory 
system alone, but they are also seen in other body systems and organs such 
as the brain [5], eye [4], gastrointestinal tract [6], renal and urinary 
structures [7], hemopoietic [8], and cardiovascular [9] system. Recent 
reports show that COVID-19 causes several cardiovascular complications 
including myocardial infarction (MI), myocarditis, heart failure (HF), 
cardiogenic shock, and sudden cardiac death (SCD) [10].
In spite of the fact that COVID-19 is commonly associated with HF in 
which the heart is unable to pump blood efficiently around the body to 
meet its demand, the biological mechanisms leading to the development of 
COVID-19-induced HF are still points of discussion. Knowledge of the 
possible mechanisms by which COVID-19 patients develop HF would help 
in the understanding and the management of HF in this cohort of patients.
Methods
The authors review the status of COVID-19-induced HF with emphasis on 
pathways leading to the development of HF. Data and information were 
collected from PubMed, Scopus, Centre for Disease Control (USA), 
Worldometer and Science Direct using the terms “SARS-CoV-2/COVID-
19 and heart,” “SARS-CoV-2/COVID-19 and heart failure,” and “SARS-
CoV-2/COVID-19 and cardiovascular complications”.
Response to SARS-CoV-2 invasion
Immediately after the invasion of either the conjunctiva, oral, or nasal 
mucosas by optimal viral load, the following pathophysiological changes 
occur in the susceptible individual.
a Extensive and generalized SARS-CoV-2 replication. SARS-CoV-2 
starts with a fast and expeditious division after entry into host cells via 
angiotensin-converting enzyme receptor 2 (ACE2) located on cell 
surfaces in the lung, heart, and epithelium of several other organ 
systems [9].
b Virus-induced infiltration of the peri-, myo-, and endocardium by 
inflammatory cells. Immune cells such as neutrophils, pro-
inflammatory monocyte/macrophages, and lymphocytes assemble 
around the areas of myocardium infiltrated by the virus [11, 12]. 
SARS-CoV-2 particles have been identified in the myocardium of 
patients with COVID-19 [13]
c Activation of cytokines: neutrophils, pro-inflammatory 
monocyte/macrophages, and lymphocytes infiltrating the myocardium 
around the viral (SARS-CoV-2) inclusions release a myriad of 
cytokines. These cytokines, including but not limited to monocyte 
chemoattractant protein-1, interleukin-1β, interleukin-6, and tumor 
necrosis factor-α, create a “cytokine storm” in COVID-19 patients 
[14].
d Endothelial injury and micro-thrombosis are induced in the body of 
the victim. Several reports showed that the endothelium of several 
organs contains ACE2 receptor (SARS-CoV-2 receptor) and invasion 
of these epithelial membranes by SARS-CoV-2 results in immediate 
inflammatory response with the activation of the complement and 
thrombin systems. In addition, the platelet and white blood cells 
congregate at the site of SARS-CoV-2-induced lesions in the 
epithelium. All of these pathophysiological reactions culminate in the 
development of coagulopathy with elevated levels of D-dimer and 
fibrin degradation products (FDPs) [15] and eventual development of 
micro-thrombi [16].
e Acute respiratory distress syndrome (ARDS)/respiratory failure is the 
most lethal insult to the body of the patient. In addition to SARS-CoV-
2-induced myocardial lesions, endothelial injury and micro-
thrombosis, the impact of poor oxygen supply to the heart cannot be 
ignored. ARDS/Respiratory failure leads to hypoxia, which in turn 
could lead to the development of HF. Although it is known that the 
most common outcome of COVID-19 is respiratory failure [17], the 
hypoxia induced by respiratory failure may put additional strain on the 
heart.
Correlation between COVID-19 and heart failure
Myocardial injury is particularly common in patients with COVID-19. In a 
retrospective study of 191 COVID patients in Wuhan, China, HF is the 4th 
most common outcome of the disease [17]. In another study of 131 patients 
who have died of COVID-19, 49% of all deaths were attributed to HF in 
patients without a previous history of cardiovascular diseases [18]. It is 
thus evident that after sepsis, respiratory failure including acute respiratory 
distress syndrome (ARDS), cardiac injury, and HF are the most common 
sequelae of COVID-19. Since COVID-19 is still evolving, the extent of the 
degree of cardiac involvement is still elusive. It will take time before we 
know how common or severe cardiac complications of COVID-19 are.
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Putative mechanisms by which COVID-19 induces heart 
failure Infiltration of heart by inflammatory cells
Reports on 61 retrospective cases of children who died of COVID-19 show 
that SARS-CoV-2 infection is not limited to the lung alone but also 
observed in the heart. The SARS-CoV-2-induced infection leads to the 
formation of viral inclusions with subsequent attraction of 
monocytes/macrophages, neutrophils, and lymphocytes [19, 20]. The virus-
induced infiltration by inflammatory cells is associated with edema. All of 
these factors may have an adverse impact on the function of the heart, 
resulting in the development of HF. In fact, a virus-induced cell-mediated 
autoimmune response leads to myocarditis. This type of virus-induced 
myocarditis causes edema of the myocardial interstitium coupled with 
necrosis of myocardium and interstitial connective tissue. Myocarditis may 
progress to dilated cardiomyopathy (DCM) [21, 22]. Moreover, DCM 
patients who harbor cardiotropic viruses coupled with myocarditis have a 
much poorer prognosis [23]. Epidemiological studies showed that 
myocarditis is present in about 20–30% of patient suffering from COVID-
19 [24]. Whether HF develops or not depends on the severity of the cardiac 
lesion, comorbidities, age, and many other factors.
Mitigation of the number and severity of infiltration by pro-inflammatory 
cells with a reduction in the associated edema may help in the prevention 
of COVID-19-induced cardiac lesions and HF. This may be effective with 
the administration of anti-inflammatory drugs and diuretics. Indeed, 
diuretics are included in the regimen for the treatment of COVID-19 
patients [3]. The putative route by which SARS-CoV-2 is transmitted from 
the air to the lungs and through pulmonary capillaries to the heart is shown 
in Fig. 1.
Fig. 1
This schematic diagram illustrates the passage of SARS-CoV-2 from the air 
via the nostrils and then into the pulmonary alveoli. From here, the viral 
particles make their way into the alveolar capillaries and into both the 
pulmonary and systemic circulations. SARS-CoV-2 particles from coronary 
arteries get into the myocardium via smaller arteries. SARS-CoV-2 particles 
are surrounded by inflammatory cells (monocyte/microphage, neutrophils, 
and lymphocytes). These pro-inflammatory cells release cytokines such as 
interleukin-1β, interleukin-6 and monocyte chemoattractant protein-1, and 
tumor necrosis factor-α. LV left ventricle, RV right ventricle
Pro-inflammatory cytokines
The body system of SARS-CoV-2-infected individual reacts to viral 
infiltration by releasing a large variety of cytokines [15, 25]. Monocyte 
chemoattractant protein-1 is one of the cytokines that increases 
significantly after the onset of COVID-19. It is also a major regulator for 
the migration and infiltration of the monocytes/macrophages system [26] 
to the site of SARS-CoV-2 infection. Therefore, the accumulation of 
macrophages around viral inclusions may impose a mechanical disruption 
of the function of the heart.
Another important member of the cytokine family associated with COVID-
19 is interleukin-1β, a key regulator of inflammatory response, with the 
ability to stimulate the release of other cytokines such as IL-17, IL-21, and 
IL-22. Interleukin-1β and tumor necrosis factor alpha both contribute to 
pain associated with inflammation via the induction of cyclooxygenase-2 
in the nervous system [27]. This may play a role in the severe headache 
associated with COVID-19 infection. This COVID-19 associated pain, 
which can occur in joints and as headache, may persist for several weeks 
after infection [28]. Interleukin-1β also increases cell proliferation and 
differentiation [29]. The ability of interleukin-1β to promote cell 
proliferation may contribute to the thickening of the layers of the heart 
leading to cardiomyopathy. Tumor necrosis factor alpha (TNF-α) is 
secreted by many cells including macrophage, neutrophil, mast cell and 
even by cardiomyocytes [30]. TNF-α has been implicated in a variety of 
inflammatory processes including cell proliferation and fever [31]. These 
pro-inflammatory cytokines have adverse effect on the outcome of virus-
induced infection such as dengue fever [32].
These cytokines can adversely affect the function of the heart by 
facilitating the infiltration of the myocardium with 
monocyte/macrophages, neutrophils, and lymphocytes. The deposition of 
these cells within the myocardium could impair the function of the heart 
leading to HF. Moreover, the action of the cytokines could also have a 
direct effect on cardiac function.
Prevention of the inflammation caused by COVID-19 following treatment 
with either NSAID or specific monoclonal antibodies against these 
cytokines could help in the prevention of the pathological events leading to 
cardiac injury and HF. In fact, anti-inflammatory medications [33] and 
monoclonal antibodies [34] are part of the therapeutic regimens for 
COVID-19 in addition to other adjunct drugs and anti-viral medications. 
The putative pathway by which pro-inflammatory cytokines contribute to 
the development of hypoxia and HF after infection with SARS-CoV-2 is 
shown in Fig. 2.
Fig. 2
This schematic diagram depicts the inclusion of SARS-CoV-2 in the 
myocardium. Pro-inflammatory cells initially surround SARS-CoV-2 
particles to form an inclusion. Thereafter, the inflammatory cells around 
viral particles release cytokines such as monocyte chemoattractant protein-1 
(MCP-1), interleukin-1β, and tumor necrosis factor-α (TNF-α) which act as 
noxious factors to the heart resulting in hypoxia and if severe sudden cardiac 
death
Endothelial injury and micro-thrombosis
In patients who died of COVID-19, capillaritis coupled with micro-
thrombosis was observed very early during the course of the disease. Large 
thrombi, microangiopathy, and signs of disseminated intravascular 
coagulation were observed in chronic and more severe cases of COVID-19 
[16, 35]. The dysfunction of the vascular epithelium in patients with 
COVID-19 due to coagulopathy and thrombosis may cause myocardial 
infarction and HF, in addition to loss of function in other organ systems. 
Other reports show that in addition to coagulopathy, endothelial injury may 
lead to increased vascular permeability and low nitric oxide level in the 
internal layer of capillary coat [36]. All of these factors could lead to 
severe cardiac injury culminating in HF.
Some reports have shown that a combination of thrombolytic (recombinant 
tissue plasminogen) and anti-inflammatory (tocilizumab) medications can 
ameliorate the signs and symptoms of COVID-19 [37].
Acute respiratory distress syndrome (ARDS)/Respiratory 
failure
Patients with ARDS and respiratory failure will have less oxygen to supply 
the heart. It is imperative therefore that a failing lung will have adverse 
effect on the function of the heart. In order to save the heart, the lung 
should also be saved, as these two vital organs depend on each other to 
function perfectly. Previous reports have shown that the more severe the 
respiratory failure the more likely the heart will be deprived of oxygen 
leading to early heart failure [17, 18]. Hypoxia is due to a sequelae of 
respiratory failure, which in turn is a risk factor for survival in COVID-19 
patients [38].
Markers of cardiac function
Biomarkers of cardiac function are crucial to monitoring the progression of 
injury in the myocardium of COVID-19 patients. One of the most common 
biomarkers examined is troponin T. The higher the level of troponin T, the 
higher the risk of mortality in patients suffering from COVID-19 [39]. 
Troponin T is released into circulation during injury to cardiac myocyte. 
Cardiomyocytes show deranged myofibrils in a failing heart [40, 41]. 
Other biomarkers used in the assessment of cardiac function in COVID-19 
patients include N-terminal pro-B-type natriuretic peptide, D-dimer, 
ferritin, interleukin-6, creatinine kinase-myocardial band, and lactate 
dehydrogenase. These biomarkers correlate well with the level of troponin 
T. In a study of more than 400 hospitalized patients in Wuhan, China, all of 
the cardiac biomarkers measured were high in patients with COVID-19. 
The report also concluded that the higher these values, the higher the risk 
of HF and sudden cardiac deaths (SCD) [42].
It is therefore important to monitor cardiac functions as early as possible to 
prevent severe and irreversible myocardial lesions and heart failure.
Conclusion
Cardiac lesions are common complications of COVID-19. They are caused 
by factors arising from the body’s reaction to SARS-CoV-2 (viral 
inclusions, infiltrating immune cells, the effect of cytokines released by 
macrophages, lymphocytes and neutrophils, ARDS/respiratory failure-
induced hypoxia, coagulopathy resulting from endothelial injury). The 
approach to preventing the development of cardiac lesions, HF, and SCD is 
multifaceted in nature. The first and foremost approach is to prevent the 
virus from getting into the body either by social distancing or virus 
elimination by drug therapy or vaccination. A schematic illustration of the 
putative mechanisms by which COVID-19 induces HF is depicted in Fig. 
3.
Fig. 3
This schematic diagram illustrates the putative mechanisms by which 
COVID-19 induces heart failure (HF). SARS-CoV-2 inclusions within the 
myocardium may cause infiltrative restrictive cardiomyopathy leading to HF. 
Moreover, pro-inflammatory cells surrounding SARS-CoV-2 inclusions 
release cytokines such as tumor necrosis alpha (TNF-α), monocyte 
chemoattractant protein-1 (MCP-1), interleukin-1β (IL-1β), interleukin-6 
(IL-6) and many others. These cytokines increase the tissue levels of matrix 
metalloproteinases (MMPs), protease-activated receptor (PAR), nitric oxide 
synthase (NOS), severe oxidative stress, apoptosis, and edema in both the 
heart and lungs. All of these could lead to cardiac and pulmonary fibrosis 
and necrosis, eventually resulting in HF. In addition, SARS-CoV-2-induced 
lesion of the cardiovascular epithelium leads to the activation of thrombin 
and the complement systems. This activation causes disseminated 
intravascular coagulopathy (DIC) and many thrombi, which could block 
coronary arteries resulting in myocardial infarction and subsequently HF. 
Lung fibrosis and hypoxia stimulate further recruitment of pro-inflammatory 
cells, thereby initiating a vicious cycle
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